SIRIAMLAB

SIR-OAA-01 · DUO

OAA DUO

Occipital and upper cervical application zones, formulated for the cranial dermatome transition.

Version 2.1Batch OAA-2602Updated 2026-02
LanguageEnglish

Interface shown in English. Product-specific text is published in its verified source language.

What this product is for

OAA DUO exists to give practitioners a clearly delimited application field at the occipital transition, with a two-step texture sequence that supports consistent, reproducible routines.

Where it is applied

The zones listed below (application field) are the possible application areas. The product can be applied across all of these zones, or more specifically in one or several of them, in consultation with your practitioner.

Application field: head.

How to use it

  1. 01Cleanse and dry the four defined application zones.
  2. 02Bring 1 push (airless system) of phase 1 to the area indicated by your therapist or in the application zones specific for this product.
  3. 03Apply the product 2 times a day in this selected area, in a thin layer.
  4. 04Follow up by phase 2 of this product if indicated by your therapist, following the steps in the application sequence.

Application sequence

Phase 1 · Week 1–2 · 1–2 applications per day

Neurodermal release

The first texture is applied thinly on the target zone within the possible application zones, in the official zone order: suboccipital, directly below the hairline; retroauricular, behind the ear; submandibular, from the angle of the mandible towards the chin; and pre-SCM, immediately anterior to the upper portion of the sternocleidomastoid. Zone order stays identical at every session.

Phase 2 · Week 3 evening · from week 4 morning and evening

Neurodermal integration

From week 3 phase 2 is added in the evening: phase 1 in the morning on the target zone, phase 2 in the evening on that same target zone. From week 4 — or once phase 1 is finished and phase 2 is also recommended by your therapist — phase 2 is applied on the target zone in the morning and in the evening until the product is finished.

Maintenance · 1–3 sessions per week

Continued routine

The sequence is continued at a reduced cadence. Frequency, zones and observations are recorded in the professional log sheet and reviewed at agreed intervals.

What is in it

Ingredients are listed by name and function. Composition quantities are part of the controlled manufacturing documentation and are not published on this page.

  • Aqua baseAqua

    Sets the water phase that determines spreadability across a defined surface field.

  • GlycerinGlycerin

    Keeps the applied layer supple so the same field can be worked repeatedly without dryness on the skin surface.

  • Shea butterButyrospermum parkii butter

    Gives the texture enough body to stay on the applied zone rather than running along the hairline.

  • PanthenolPanthenol

    Documented as a conditioning constituent of the cutaneous topical base; contributes to a smooth, non-tacky finish.

  • TocopherolTocopherol

    Protects the lipid fraction over the shelf life of the record so successive batches stay comparable.

  • MSMDimethyl sulfone

    Documented constituent of phase 1 and phase 2 of the OAA record; kept at a low level so the texture of both steps stays light and spreadable.

  • Rosemary leaf extractRosmarinus officinalis leaf extract

    Gives phase 1 its recognisable aromatic signature, which practitioners use to distinguish the two textures during a session.

  • Magnesium chlorideMagnesium chloride

    Documented constituent of the phase 2 water phase; contributes to the lighter, faster-absorbing texture of the integration step.

Safety

  • For external cutaneous topical application on intact skin only.
  • Avoid contact with the eyes, mucous membranes and broken or irritated skin.
  • Discontinue use if irritation occurs and consult your practitioner.
  • Keep out of reach of children.
  • This is a cutaneous topical composition. It is not a medicine and makes no therapeutic claim.

Storage

Store closed and upright, away from direct sunlight and heat. Use within the period stated on the package.

Questions

Is this a medicinal product?

No. SIRIAM formulations are cutaneous topical compositions. They are described by application region and composition, not directed at a therapeutic indication but rather at regulation of the nervous system. EMG validation will need to support this further in the future.

Who determines the application region?

The region is identified by a healthcare professional using anatomical landmarks and surface maps. Our documentation supports that conversation.

Can the formulation be combined with other routines?

Combination and sequencing are decided together with the treating professional. We document composition, application and response.

Record reference

Product ID
SIR-OAA-01
Family
DUO
Version
2.1
Batch
OAA-2602
Updated
2026-02
Published by
SIRIAM LAB

Open the complete professional record

Contact the institute